Coronavirus Update: Two UK-Backed Vaccines Progress, Cross-Industry Database Launched, Roche's Schwan On COVID-19 Impact

Adenovirus and mRNA Candidates Move Into Phase I

Plus: Korea's Dong Wha readies potent antiviral for trials, and Pharming's candidate shows promise in compassionate use.  

Coronavirus globe
• Source: Shutterstock

Despite the impact of COVID-19, Roche still expects full-year sales to grow in the low- to mid-single-digit percentage range, with core earnings per share growing broadly in line with sales at constant exchange rates (CER), the company revealed this morning (22 April) after unveiling healthy first-quarter financials.

CEO Severin Schwan said that while the coronavirus pandemic outbreak "poses an unprecedented challenge in particular for healthcare systems," Roche...

Scrip Podcast

Keep up with the top pharma business news of the week. On the go.

Scrip brings you a weekly bulletin of top picks.

More from COVID-19

More from Scrip